Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?

GRACEcast by Howard (Jack) West, MD

The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.